All In Biotech

Drug Trial Radar · NCT01856218

An Open-Label Phase 1/2 Study to Assess the Safety, Efficacy and Dose of Study Drug UX003 Recombinant Human Beta-glucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7)

An Open-Label Phase 1/2 Study to Assess the Safety, Efficacy and Dose of UX003 rhGUS Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7)

Last checked: Nov 20, 2026Latest source record: Jan 4, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

3

Actual

Start

Nov 2013

Primary completion

Jul 2016

Study completion Jul 2016

Sponsor

Lead sponsor
Ultragenyx Pharmaceutical IncIndustry
Sponsor type
Industry
First posted
May 17, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 5 years, up to 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

UX003-CL201 is an open-label Phase 1/2 study to assess the safety, efficacy, and dose of UX003 in MPS 7 patients via intravenous (IV) administration every other week (QOW) for 36 weeks with up to an additional 36 weeks from the optional continuation period. Up to 5 participants, who are between 5 and 30 years of age inclusive, will be enrolled and treated with UX003. The initial 12-week treatment period will be followed by a 24-week forced dose titration period to assess the optimal dose. Participants who complete both the initial treatment and forced dose titration periods will continue treatment in a 36- week continuation period.

Conditions

  • Mucopolysaccharidosis Type 7

Interventions

  • UX003Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage Change From Baseline in Urinary Glycosaminoglycan (uGAG) Dermatan SulfateTime frame: Baseline, Week 14, Week 22, Week 30, Week 38, Week 72, and end of study (up to Week 132)
  2. Percentage Change From Baseline in uGAG Chondroitin SulfateTime frame: Baseline, Week 14, Week 22, Week 30, Week 38, Week 72, and end of study (up to Week 132)
  3. Number of Participants With Any ≥ 50% Decrease in uGAGTime frame: up to Week 132
  4. Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Deaths, and Study/Treatment DiscontinuationsTime frame: Up to 242 weeks + 30 days. SAEs were recorded beginning at the time the subject signed the informed consent form through 30 days following the last study visit. Non-serious AEs were recorded from the time of informed consent through the last study visit.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Manchester Academic Health Science Centre

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.